Immunic, Inc. hosted a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026. This event is significant as it showcases the company's ongoing efforts in developing treatments for progressive multiple sclerosis, a condition that affects many individuals worldwide.

Immunic, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a smaller reporting company listed on the Nasdaq under the ticker symbol IMUX. Based in New York, the company focuses on innovative therapies for autoimmune diseases, particularly in the field of multiple sclerosis.

According to the recent SEC filing (accession number 0001193805-26-001432), the PMS R&D Day took place via video conference from 12:30 p.m. to 2:00 p.m. ET. The company utilized a presentation during the event, which is attached as Exhibit 99.1 to the filing.

This event may have implications for various stakeholders, including investors, healthcare professionals, and patients interested in advancements in MS treatments. As Immunic discusses its research and development initiatives, it is likely to attract attention from those monitoring the pharmaceutical sector's progress in treating progressive multiple sclerosis.

Details regarding future events or developments were not specified in the filing.

During the PMS R&D Day, Immunic is expected to discuss its development programs, particularly focusing on vidofludimus calcium, which is being evaluated for its potential to treat progressive multiple sclerosis. The presentation will likely include insights into preclinical and clinical data supporting the efficacy and safety of this treatment.

The company has emphasized the importance of this event in updating stakeholders on the progress of its clinical trials and the anticipated timelines for further developments. Immunic's management may also address the current market landscape and how their innovations fit within the broader context of multiple sclerosis therapies.

Furthermore, the SEC filing indicates that Immunic is not classified as an emerging growth company, which may influence its regulatory obligations and reporting requirements. This status can affect how the company approaches its financial disclosures and investor communications.

Details regarding the specific content of the presentation or any announcements made during the webinar have not been disclosed in the filing. Investors and interested parties will need to refer to the attached Exhibit 99.1 for comprehensive information shared during the event.